LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Strona główna・Stock List・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Closed

SectorHealthcare

41.21 -0.91

Buy Sell

Overview

Share price change

24h

Current

Min

41.2

Max

41.72

Key metrics
By Trading Economics
Income	-6.2M -91M
Profit margin	-867.293
Employees	316
EBITDA	4M -90M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+32.15% upside

Dividends
By Dow Jones
Next Earnings	26 lut 2026

Market Stats
By TradingEconomics
Market Cap	49M 3.3B
Previous open	42.12
Previous close	41.21

News Sentiment

By Acuity

50%

144 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

34.81 / 38.24 Support & Resistance

Xenon Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 lut 2026, 16:32 UTC

Earnings

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

14 lut 2026, 22:02 UTC

Earnings

Looking for Dividends? Consider Europe. -- Barrons.com

14 lut 2026, 09:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

13 lut 2026, 21:57 UTC

Earnings

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13 lut 2026, 21:20 UTC

Earnings

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13 lut 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13 lut 2026, 20:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13 lut 2026, 20:45 UTC

Market Talk

Dollar Pares Down Early Losses -- Market Talk

13 lut 2026, 20:39 UTC

Market Talk

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13 lut 2026, 20:28 UTC

Market Talk

Oil Settles Week Lower -- Market Talk

13 lut 2026, 19:51 UTC

Earnings

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13 lut 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 lut 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 lut 2026, 19:29 UTC

Earnings

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13 lut 2026, 18:18 UTC

Acquisitions, Mergers, Takeovers

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

13 lut 2026, 17:52 UTC

Earnings

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

13 lut 2026, 17:16 UTC

Earnings

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13 lut 2026, 17:10 UTC

Acquisitions, Mergers, Takeovers

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

13 lut 2026, 16:59 UTC

Earnings

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

13 lut 2026, 16:39 UTC

Acquisitions, Mergers, Takeovers

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

13 lut 2026, 16:11 UTC

Earnings

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

13 lut 2026, 16:07 UTC

Market Talk

Hungarian Forint Could Rise Further -- Market Talk

13 lut 2026, 15:54 UTC

Earnings

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

13 lut 2026, 15:26 UTC

Market Talk

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

13 lut 2026, 15:01 UTC

Earnings

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

13 lut 2026, 15:00 UTC

Earnings

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

13 lut 2026, 14:50 UTC

Market Talk

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

13 lut 2026, 14:44 UTC

Earnings

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

13 lut 2026, 14:22 UTC

Market Talk

Earnings

Global Energy Roundup: Market Talk

Peer Comparison

Price change

Xenon Pharmaceuticals Inc Forecast

Price Target

By TipRanks

32.15% upside

12 Months Forecast

Average 55 USD 32.15%

High 66 USD

Low 44 USD

Based on 10 Wall Street analysts offering 12 month price targets forXenon Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to Xenon Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

34.81 / 38.24Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

144 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.